David M. Jackman

David M. Jackman, MD is an Assistant Professor of Medicine at Harvard Medical School and a practicing physician at Dana-Farber Cancer Institute, where he serves as Medical Director for Clinical Pathways and New Business Initiatives. He specializes in thoracic oncology through the Lowe Center for Thoracic Oncology, treating complex cases of lung cancer and mesothelioma while advancing cancer care delivery systems.

His educational background includes:

• Medical Degree: Brown University School of Medicine (2000)
• Residency: Beth Israel Deaconess Medical Center (Internal Medicine)
• Fellowship: Dana-Farber/Partners CancerCare (Medical Oncology)

Dr. Jackman's research focuses on developing targeted therapies for lung cancer and mesothelioma, with significant contributions to optimizing clinical pathways and healthcare delivery models. His work bridges molecular oncology with systemic improvements in cancer treatment protocols, emphasizing patient-centered care coordination and evidence-based pathway implementation across multidisciplinary teams.

Board certified in Medical Oncology (2006), he treats non-small cell lung cancer, small cell lung cancer, mesothelioma, and thymic tumors through clinical practice at Dana-Farber's Boston and Chestnut Hill locations.

No scientific awards or honors were documented in the provided materials.

While specific student advisement details are unavailable, his leadership in clinical pathways suggests mentorship of oncology fellows and practitioners in care delivery innovation. No grant funding information was disclosed in the source text.

He operates within Dana-Farber's Lowe Center for Thoracic Oncology, collaborating with medical, surgical, and radiation oncology teams to integrate research findings into standardized treatment protocols while directing new business initiatives for cancer care infrastructure.